Drugs / PBLTT52CAR19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04557436 | Aug 2020 → Mar 2024 | B-cell acute lymphoblastic leukemia | Great Ormond Street Hospital for Children NHS Foundation Trust | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBLTT52CAR19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04557436 ↗ |
| Modality | Cell therapy | “PBLTT52CAR19 modified T cells are allogenic engineered human T cells” NCT04557436 ↗ |